Navitor Pharmaceuticals

Navitor Pharmaceuticals

  • Founded: 2014
  • Location: Cambridge, MA
  • Employee range: 11 - 50
  • Clinical stage: Clin1
  • Therapy area: Depression
  • Drug types: PSY, NPH, GEN, CVV, NEU
  • Lead product: NV-5138
  • Product link:
  • Funding: $33M B Dec 2015, $23.5M A Jun 2014


Short description:

Drug discovery related to central metabolic signaling pathways

Drug notes:

Undisclosed RD heart failure, kidney diseases, epilepsy, genetic diseases

Long description:

Navitor Pharmaceuticals is a biopharmaceutical company delving into the world of cellular metabolism signaling pathways. Their proprietary drug discovery platform focuses on mTORC1, which plays a critical role in protein synthesis and cellular growth. By targeting mTORC1, Navitor aims to develop therapeutics for a range of diseases with disruption in this signaling pathway, including depression, chronic kidney disease, heart failure, and some genetic disorders. Their proprietary platform allows Navitor to discover and develop small molecule drugs that selectively targets and modulates mTORC1. Navitor was founded in 2010 with headquarters located in Cambridge, MA.


© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy